MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

AbbVie Inc

Fechado

SetorSaúde

189.23 -1.23

Visão Geral

Variação de preço das ações

24h

Atual

Mín

188.52

Máximo

189.89

Indicadores-chave

By Trading Economics

Rendimento

1.3B

1.3B

Vendas

-1.8B

13B

P/E

Médio do Setor

81.846

39.857

EPS

2.46

Rendimento de Dividendos

3.53

Margem de lucro

9.66

Funcionários

55,000

EBITDA

3.2B

3.7B

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+10.83% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

3.53%

2.42%

Próximos Ganhos

31 de jul. de 2025

Próxima data de dividendos

15 de ago. de 2025

Próxima data de ex-dividendo

14 de out. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-5B

338B

Abertura anterior

190.46

Fecho anterior

189.23

Sentimento de Notícias

By Acuity

24%

76%

51 / 376 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

AbbVie Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

30 de jun. de 2025, 13:02 UTC

Aquisições, Fusões, Aquisições de Empresas

AbbVie Agrees to Acquire Capstan Therapeutics for $2.1 Billion in Cash

25 de abr. de 2025, 13:57 UTC

Ganhos

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised -- Update

25 de abr. de 2025, 12:52 UTC

Ganhos

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised

9 de abr. de 2025, 18:18 UTC

Grandes Movimentos do Mercado

Pharma Shares Reverse Losses After Tariff Pause

9 de abr. de 2025, 09:39 UTC

Grandes Movimentos do Mercado

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

30 de jun. de 2025, 12:47 UTC

Aquisições, Fusões, Aquisições de Empresas

AbbVie Agrees to Acquire Capstan Therapeutics for $2.1B in Cash

30 de jun. de 2025, 12:33 UTC

Aquisições, Fusões, Aquisições de Empresas

AbbVie Will Acquire Capstan, Including CPTX2309, a Potential First-In-Class in Vivo tLNP anti-CD19 CAR-T Therapy Candidate >ABBV

30 de jun. de 2025, 12:33 UTC

Aquisições, Fusões, Aquisições de Empresas

AbbVie : Proposed Acquisition Strengthens Commitment to Transforming Patient Care With Capstan's Innovative tLNP Platform Technology >ABBV

30 de jun. de 2025, 12:32 UTC

Aquisições, Fusões, Aquisições de Empresas

AbbVie Will Pay Up to $2.1B in Cash at Closing to Acquire Capstan >ABBV

30 de jun. de 2025, 12:31 UTC

Aquisições, Fusões, Aquisições de Empresas

AbbVie To Acquire Capstan Therapeutics, Further Strengthening Commitment To Transforming Patient Care In Immunology >ABBV

7 de mai. de 2025, 09:30 UTC

Principais Notícias

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

28 de abr. de 2025, 12:44 UTC

Ganhos

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

28 de abr. de 2025, 09:33 UTC

Ganhos

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25 de abr. de 2025, 16:03 UTC

Ganhos

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25 de abr. de 2025, 14:00 UTC

Principais Notícias
Ganhos

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 de abr. de 2025, 12:24 UTC

Principais Notícias
Ganhos

AbbVie Stock Jumps as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 de abr. de 2025, 12:03 UTC

Principais Notícias
Ganhos

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 de abr. de 2025, 11:43 UTC

Ganhos

AbbVie 1Q U.S. HUMIRA Rev $744M >ABBV

25 de abr. de 2025, 11:43 UTC

Ganhos

AbbVie 1Q International HUMIRA Rev $377M >ABBV

25 de abr. de 2025, 11:43 UTC

Ganhos

AbbVie 1Q Global Skyrizi Rev $3.43B >ABBV

25 de abr. de 2025, 11:43 UTC

Ganhos

AbbVie 1Q Net $1.29B >ABBV

25 de abr. de 2025, 11:43 UTC

Ganhos

AbbVie 1Q Global Net Rev From Oncology Portfolio $1.63B >ABBV

25 de abr. de 2025, 11:43 UTC

Ganhos

AbbVie 1Q Global IMBRUVICA Rev $738M >ABBV

25 de abr. de 2025, 11:43 UTC

Ganhos

AbbVie 1Q EPS 72c >ABBV

25 de abr. de 2025, 11:43 UTC

Ganhos

AbbVie 1Q Adj EPS $2.46 >ABBV

25 de abr. de 2025, 11:43 UTC

Ganhos

AbbVie 1Q Rev $13.34B >ABBV

25 de abr. de 2025, 11:43 UTC

Ganhos

AbbVie Sees FY Adj EPS $12.09-Adj EPS $12.29 >ABBV

14 de mar. de 2025, 09:30 UTC

Principais Notícias

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

3 de mar. de 2025, 15:04 UTC

Aquisições, Fusões, Aquisições de Empresas

AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. -- IBD

28 de fev. de 2025, 12:00 UTC

Principais Notícias

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

Comparação entre Pares

Variação de preço

AbbVie Inc Previsão

Preço-alvo

By TipRanks

10.83% parte superior

Previsão para 12 meses

Média 212.13 USD  10.83%

Máximo 250 USD

Mínimo 170 USD

Com base em 18 analistas de Wall Street que oferecem metas de preço de 12 meses para AbbVie Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

18 ratings

12

Comprar

6

Manter

0

Vender

Pontuação Técnica

By Trading Central

180.37 / 195.54Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

51 / 376 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.